Related Experiment Videos
Potential role for gene therapy in the enhancement of fracture healing
C Niyibizi1, A Baltzer, C Lattermann
1Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, PA, USA.
Abstract:
Various proteins have the potential to initiate and accelerate fracture healing. Although osteogenic growth factors are the most prominent of these, there also may be important roles for other agents including growth factor receptors, angiogenic factors, and cytokine antagonists. Gene based delivery systems offer the potential to achieve therapeutic levels of these proteins locally within the fracture site for sustained times. Moreover, these delivery systems may deliver their products in a more biologically active form than that achieved by the exogenous application of recombinant proteins. Genes may be transferred to fractures by direct in vivo delivery or by indirect ex vivo delivery, using viral or nonviral vectors. Two examples are described in this article. With an ex vivo procedure, it was possible to transfer lac Z and neo(r) marker genes to the bones of mice, using retroviral transduction of bone marrow stromal cells. Gene expression in vivo persisted for several weeks. This procedure has the advantage of providing not only gene products but also osteoprogenitor cells to sites of bone healing. In vivo, local transfer of the lucerifase and lac Z marker genes was accomplished in a segmental defect model in the rabbit using adenoviral vectors. Under these conditions, gene expression in most tissues in and around the defect lasted between 2 and 6 weeks. These data encourage additional development of gene therapy for fracture healing. Such developments should go hand in hand with studies in the basic biology of fracture healing.
Insights
Gene therapy shows promise for accelerating fracture healing by delivering therapeutic proteins directly to bone. This approach, using viral vectors for gene transfer, offers sustained and biologically active protein delivery for enhanced bone repair.
Area of Science:
- Regenerative Medicine
- Orthopedic Surgery
- Molecular Biology
Background:
- Fracture healing involves various proteins, including osteogenic growth factors, receptors, angiogenic factors, and cytokine antagonists.
- Gene-based delivery systems offer a promising strategy for localized, sustained, and biologically active protein delivery at fracture sites.
- Traditional recombinant protein application may not achieve the same therapeutic efficacy as gene-based methods.
Purpose of the Study:
- To investigate the potential of gene therapy for enhancing fracture healing.
- To demonstrate the feasibility of both ex vivo and in vivo gene transfer methods for bone repair.
- To evaluate the duration and efficacy of gene expression in fracture healing models.
Main Methods:
- Ex vivo gene transfer: Retroviral transduction of bone marrow stromal cells with lac Z and neo(r) marker genes in mice.
- In vivo gene transfer: Adenoviral vector delivery of lucerifase and lac Z marker genes into a rabbit segmental defect model.
- Monitoring of gene expression persistence and biological activity at the fracture site.
Main Results:
- Ex vivo approach successfully transferred marker genes, with sustained in vivo gene expression for several weeks, providing both gene products and osteoprogenitor cells.
- In vivo adenoviral vector delivery resulted in gene expression lasting 2-6 weeks in the rabbit segmental defect model.
- Both methods demonstrated successful gene transfer and expression relevant to fracture healing.
Conclusions:
- Gene therapy holds significant potential for accelerating and improving fracture healing.
- Both ex vivo and in vivo gene delivery strategies are viable for bone repair applications.
- Further research into gene therapy for fracture healing, alongside basic biology studies, is warranted.